Pharma BD Deal Intelligence
BioNTech's ADC bet is paying off: $170M upfront for DualityBio's DB-1303 and DB-1311 against ~$1.5B in milestones, and lead asset DB-1303 (T-Pam) won FDA Breakthrough Therapy Designation in endometrial cancer by December 2023 — though the alliance kept expanding, adding a third ADC that August.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BioNTech expanded its antibody-drug conjugate portfolio through a deal with China's Duality Biologics, bringing in HER2-targeting DB-1303 and…
Germany's BioNTech said on Monday it had signed a deal worth up to $1.7 billion with Chinese biotech Duality Biologics to develop antibody-drug conjugates for…
China's NMPA accepted a BLA for trastuzumab pamirtecan (T-Pam; DB-1303/BNT323) for 2L unresectable/metastatic HER2-positive breast cancer, based on the Phase…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
In April 2023 BioNTech and Duality Biologics (DualityBio) formed a global strategic partnership giving BioNTech development and commercialization rights (ex-Greater China) to two clinical-stage topoisomerase-1-inhibitor antibody-drug conjugates from DualityBio's DITAC platform: HER2-directed DB-1303 (BNT323) and B7-H3-directed DB-1311 (BNT324). DualityBio received $170M upfront plus up to ~$1.5B in development, regulatory and commercial milestones and tiered royalties (~$1.7B headline value). On August 7, 2023 the alliance was expanded to add a third ADC, the TROP2-directed DB-1305 (BNT325). The lead asset, DB-1303/BNT323 (INN trastuzumab pamirtecan, 'T-Pam'), has since de-risked materially: FDA granted Breakthrough Therapy Designation in advanced endometrial cancer (Dec 2023); the China Phase 3 DB-1303-O-3001 trial met its primary PFS endpoint in 2L HER2-positive metastatic breast cancer versus T-DM1 (Sep 2025); China's NMPA accepted a BLA for that indication (Apr 9, 2026); and a US FDA BLA in pretreated endometrial cancer is planned for later in 2026. The B7-H3 ADC DB-1311/BNT324 has advanced into a Phase 3 trial in metastatic castration-resistant prostate cancer (BNT324-03, vs docetaxel) and holds FDA Fast Track designation in mCRPC.
50K US cases/yr · $7.0B Global HER2-directed ADC market, 2023 (Enhertu + Kadcyla combined) · ~$170M BioNTech combined upfront payments for both ADC programs (~$1.7B total deal value with milestones)
HER2 (ERBB2) is a receptor tyrosine kinase overexpressed or amplified in multiple solid-tumor types. In breast cancer, classical HER2-positive (IHC 3+ or ISH-amplified) disease represents approximately 15-20% of invasive breast cancer (~50,000 US patients/year of ~316,950 new diagnoses projected for 2026 per ACS); HER2-low (IHC 1+ or 2+/ISH-negative) accounts for an additional 45-55% of HR+ and TNBC cases, a category validated commercially by trastuzumab deruxtecan (Enhertu) in DESTINY-Breast04 (2022). HER2-expressing gastric/gastroesophageal adenocarcinoma accounts for approximately 15-20% of advanced gastric cancer (~5,000-6,000 US new diagnoses/year). HER2 overexpression also occurs in colorectal cancer (3-5%), endometrial (serous ~20-30%), biliary tract, urothelial, salivary duct, and NSCLC (HER2-mutant ~2-4%, HER2-expressing higher). Approved HER2-directed ADCs: trastuzumab emtansine (Kadcyla, Roche, TPO/DM1 payload, approved 2013) and trastuzumab deruxtecan (Enhertu, Daiichi/AstraZeneca, TOPO1i DXd payload, approved 2019 breast/2021 gastric/2024 HER2-low/2024 HER2-ultra-low). The TOPO1i payload class (camptothecin derivatives) has become the dominant ADC payload chemistry, producing deep and durable responses with a bystander-killing effect on heterogeneous HER2 expression.
The HER2-ADC landscape is dominated by Enhertu (trastuzumab deruxtecan, Daiichi/AstraZeneca), which produced ~$2.6B in 2023 sales and has label expansions across HER2-positive breast, HER2-low breast, HER2-ultra-low breast, HER2-positive gastric, HER2-mutant NSCLC, and pan-tumor HER2-positive (2024 accelerated approval). Kadcyla (trastuzumab emtansine, Roche) remains the adjuvant HER2-positive breast standard post-neoadjuvant. Next-generation HER2-ADC competitors to DualityBio's DB-1303 (now BNT323/trastuzumab pamirtecan): MediLink/Eisai's MRG002 (Phase 2 China); Zymeworks/BeiGene's zanidatamab zovodotin (ZW49, HER2 biparatopic ADC, Phase 2); Innovent/Regeneron's ADC programs; Ambrx's ARX788 (Phase 2/3); Sutro's luveltamab tazevibulin (tubulin payload); and Daiichi's next-gen DS-7300 (HER3 TOPO1i) establishing the broader HER3/HER2/TROP2 TOPO1i ADC paradigm. B7-H3 ADCs (DB-1311/BNT324) competitors include: Daiichi-Sankyo ifinatamab deruxtecan (I-DXd, Phase 3 IDeate in SCLC), MacroGenics enoblituzumab (B7-H3 mAb, no payload), GSK GSK5733584 (B7-H3 ADC), and Mersana's XMT-1660 B7-H3 ADC. DualityBio's differentiation is proprietary DITAC linker-payload chemistry aiming for improved therapeutic index vs first-generation deruxtecan and comparable bystander effects; BioNTech gains clinical-stage ADC breadth in a modality it had lacked.
DualityBio and BioNTech expanded the April 2023 alliance to add TROP2 ADC DB-1305 (ex-Greater China) for upfront, milestones and tiered royalties.
FDA granted BTD to lead ADC BNT323/DB-1303 (trastuzumab pamirtecan) in advanced endometrial cancer post immune-checkpoint-inhibitor progression.
China Phase 3 DB-1303-O-3001 met its primary PFS endpoint vs T-DM1 in previously treated HER2-positive metastatic/unresectable breast cancer.
First regulatory filing for the lead deal asset: NMPA accepted the BLA for T-Pam (DB-1303/BNT323) in 2L HER2-positive mBC; US FDA BLA in endometrial cancer planned later in 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| BioNTech SE / Duality Biologics (Suzhou) Co. Ltd. (this deal) | 2023 | $1.7B | — |
| BioNTech SE / Biotheus Inc. (Pumai Biotechnology) | 2024 | $950M | — |
| BioNTech SE / Kite Pharma (Gilead Sciences) | 2021 | $250M | — |
| BioNTech SE / CureVac N.V. | 2025 | $1.2B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
← Browse all deals · How we score deals
More: 2023 deals · BioNTech SE deals · Oncology deals